V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Revvity Executive Compensation (FY25)

RVTY · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Prahlad R. Singh
Latest say-on-pay support
=
April 28, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Revvity

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 1, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Revvity brief$1,500Get the executive brief
Velarion Member, one year
368 figures on this page: 357 cited to the filing that reported them, 11 calculated from figures it prints. See the citations

More on Revvity

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Prahlad R. Singh: $11,926,615 → $13,809,549 (15.8% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Revvity's chief executive and what were they paid?
Total compensation for Prahlad R. Singh, President and Chief Executive Officer, came to $13,809,549 in fiscal 2025. Compared with the $11,926,615 reported for fiscal 2024, Singh's total was 15.8% higher.
What was Revvity's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 96.2% of votes cast for or against in favor at the meeting held April 28, 2026.
Which companies are in Revvity's peer group?
Companies named in the disclosed peer group include 10X Genomics, Inc., Agilent Technologies, Inc., Avantor, Inc., Becton, Dickinson and Company and Bio-Rad Laboratories, Inc., among others. The 2025 LTIP Relative TSR Comparator Group (supplemental) names 10X Genomics, Inc., Becton, Dickinson and Company, Charles River Laboratories International, Inc., Haemonetics Corporation and IQVIA Holdings Inc., among others. Companies named in the Compensation Peer Group include Agilent Technologies, Inc., Avantor, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation and Bruker Corporation, among others.
What is Revvity's chief executive pay ratio?
The company reported a chief executive pay ratio of 239:1 for fiscal 2025, against median employee compensation of $57,745.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Prahlad Singh
Chief Executive Officer
◇—◇◇◇—◇◇
Joel Goldberg
Senior Vice President, Administration, General Counsel and Secretary
◇—◇◇◇—◇◇
James Mock
Former Senior Vice President and Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Tajinder Vohra
Senior Vice President Global Operations
◇—◇◇◇—◇◇
Daniel Tereau
Senior Vice President, Strategy and Business Development
◇—◇◇◇—◇◇
Maxwell Krakowiak
Senior Vice President and Chief Financial Officer
◇◇◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Prahlad Singh
Chief Executive Officer
◇—◇◇◇—◇◇
Maxwell Krakowiak
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Joel Goldberg
Senior Vice President, Administration, General Counsel and Secretary
◇—◇◇◇—◇◇
Tajinder Vohra
Senior Vice President, Global Operations
◇—◇◇◇—◇◇
Miriame Victor
Senior Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Prahlad Singh
Chief Executive Officer
◇—◇◇◇—◇◇
Joel Goldberg
Senior Vice President, Administration, General Counsel and Secretary
◇—◇◇◇—◇◇
Maxwell Krakowiak
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Miriame Victor
Senior Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Tajinder Vohra
Senior Vice President, Global Operations
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Prahlad R. Singh
President and Chief Executive Officer
◇—◇◇◇—◇◇
Maxwell Krakowiak
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Miriame Victor
Senior Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Joel S. Goldberg
Senior Vice President, Administration, General Counsel and Secretary
◇—◇◇◇—◇◇
Tajinder S. Vohra
Senior Vice President, Global Operations
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Joel S. GoldbergRSU◇——◇——◇
Joel S. GoldbergPSU◇◇◇—◇—◇
Joel S. GoldbergOPTION◇——◇—◇◇
Maxwell KrakowiakRSU◇——◇——◇
Maxwell KrakowiakPSU◇◇◇—◇—◇
Maxwell KrakowiakOPTION◇——◇—◇◇
Maxwell KrakowiakOPTION◇——◇—◇◇
Miriame VictorPSU◇◇◇—◇—◇
Miriame VictorRSU◇——◇——◇
Miriame VictorOPTION◇——◇—◇◇
Miriame VictorOPTION◇——◇—◇◇
Prahlad R. SinghPSU◇◇◇—◇—◇
Prahlad R. SinghRSU◇——◇——◇
Prahlad R. SinghOPTION◇——◇—◇◇
Tajinder S. VohraOPTION◇——◇—◇◇
Tajinder S. VohraRSU◇——◇——◇
Tajinder S. VohraPSU◇◇◇—◇—◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Tajinder S. VohraOption◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Miriame VictorOption◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
PSU◇◇——
Maxwell KrakowiakOption◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
Option◇—◇—
Prahlad R. SinghOption◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Joel S. GoldbergRSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Tajinder S. Vohra
Senior Vice President · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Alexis P. Michas
Board chair
◇◇———◇◇
Samuel R. Chapin
◇◇————◇
Peter Barrett, PhD
◇◇————◇
Michel Vounatsos
◇◇————◇
Sophie V. Vandebroek, PhD
◇◇———◇◇
Frank R. Witney, PhD
◇◇———◇◇
Michelle McMurry-Heath, MD, PhD
◇◇————◇
Michael A. Klobuchar
◇◇————◇
Pascale Witz
◇◇————◇
Prahlad R. Singh, PhD served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 10X Genomics, Inc. TXG
  • Agilent Technologies, Inc. A
  • Avantor, Inc. AVTR
  • Becton, Dickinson and Company BDX
  • Bio-Rad Laboratories, Inc. BIO
  • Bio-Techne Corporation TECH
  • Bruker Corporation BRKR
  • Catalent, Inc. CTLT
  • Charles River Laboratories International, Inc. CRL
  • Danaher Corporation DHR
  • Exact Sciences Corporation EXAS
  • Haemonetics Corporation HAE
  • Hologic, Inc. HOLX
  • Illumina, Inc. ILMN
  • IQVIA Holdings Inc. IQV
  • Laboratory Corporation of America Holdings LH
  • Medpace Holdings, Inc. MEDP
  • Mettler-Toledo International Inc. MTD
  • Myriad Genetics, Inc. MYGN
  • Natera, Inc. NTRA
  • Neogen Corporation NEOG
  • QIAGEN N.V. QGEN
  • Quest Diagnostics Incorporated DGX
  • QuidelOrtho Corporation QDEL
  • Repligen Corporation RGEN
  • Roper Technologies, Inc. ROP
  • Tecan Group AG symbol not shown
  • Teledyne Technologies Incorporated TDY
  • Teleflex Incorporated TFX
  • The Cooper Companies, Inc. COO
  • Thermo Fisher Scientific Inc. TMO
  • Waters Corporation WAT
2025 LTIP Relative TSR Comparator Group (supplemental)
  • 10X Genomics, Inc. TXG
  • Becton, Dickinson and Company BDX
  • Charles River Laboratories International, Inc. CRL
  • Haemonetics Corporation HAE
  • IQVIA Holdings Inc. IQV
  • Laboratory Corporation of America Holdings LH
  • Medpace Holdings, Inc. MEDP
  • Mettler-Toledo International Inc. MTD
  • Myriad Genetics, Inc. MYGN
  • Natera, Inc. NTRA
  • Neogen Corporation NEOG
  • Quest Diagnostics Incorporated DGX
  • Repligen Corporation RGEN
  • Roper Technologies, Inc. ROP
  • Tecan Group AG symbol not shown
  • Teledyne Technologies Incorporated TDY
  • Teleflex Incorporated TFX
Compensation Peer Group
  • Agilent Technologies, Inc. A
  • Avantor, Inc. AVTR
  • Bio-Rad Laboratories, Inc. BIO
  • Bio-Techne Corporation TECH
  • Bruker Corporation BRKR
  • Catalent, Inc. CTLT
  • Danaher Corporation DHR
  • Exact Sciences Corporation EXAS
  • Hologic, Inc. HOLX
  • Illumina, Inc. ILMN
  • QIAGEN N.V. QGEN
  • QuidelOrtho Corporation QDEL
  • The Cooper Companies, Inc. COO
  • Thermo Fisher Scientific Inc. TMO
  • Waters Corporation WAT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 28, 2026=◇◇◇
2024April 22, 2025=◇◇◇
2023April 23, 2024=◇◇◇
2022April 25, 2023=◇◇◇
2021April 26, 2022=◇◇◇
2020April 27, 2021=◇◇◇
2019April 28, 2020=◇◇◇
2018April 23, 2019=◇◇◇
2017April 24, 2018=◇◇◇
2016April 25, 2017=◇◇◇
2015April 26, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Prahlad R. Singh (President and Chief Executive Officer), FY2025 total compensation $13,809,549 (base salary $1,129,231) [exec_comp, SEC accession 0001193125-26-107266, filed 2026-03-16]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Revvity files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Revvity disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Revvity sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Revvity's disclosed peer group is defensible, who names Revvity back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
368 figures on this page: 357 cited to the filing that reported them, 11 calculated from figures it prints.
357 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001193125-26-201401
  2. 0001193125-26-107266
    2025 Director Compensation · 2025 Grants of Plan-Based Awards · CEO Pay Ratio · Compensation Discussion and Analysis · and 3 more sections
  3. 0001193125-25-096747
  4. 0001193125-25-052522
    Summary Compensation Table
  5. 0001193125-24-110060
  6. 0001193125-24-066406
    Summary Compensation Table
  7. 0001193125-23-126948
  8. 0001193125-23-063847
    Summary Compensation Table
  9. 0001193125-22-133586
  10. 0001193125-21-144984
  11. 0001193125-20-130958
  12. 0001193125-19-117178
  13. 0001193125-18-131329
  14. 0001193125-17-148115
  15. 0001193125-16-559458
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Revvity executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/RVTY (accessed 2026).
Short form: data: Velarion

The paid brief for Revvity

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Revvity and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Revvity discloses

The companies named in RVTY's own disclosed peer group.

10X Genomics, Inc.Agilent Technologies, Inc.Avantor, Inc.Becton, Dickinson and CompanyBio-Rad Laboratories, Inc.Bio-Techne CorporationBruker CorporationCatalent, Inc.Charles River Laboratories International, Inc.Danaher CorporationExact Sciences CorporationHaemonetics CorporationHologic, Inc.Illumina, Inc.IQVIA Holdings Inc.Laboratory Corporation of America HoldingsMedpace Holdings, Inc.Mettler-Toledo International Inc.Myriad Genetics, Inc.Natera, Inc.Neogen CorporationQuest Diagnostics IncorporatedQuidelOrtho CorporationRepligen Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy